HK1083096A1 - Casr antagonist casr - Google Patents
Casr antagonist casrInfo
- Publication number
- HK1083096A1 HK1083096A1 HK06105438.3A HK06105438A HK1083096A1 HK 1083096 A1 HK1083096 A1 HK 1083096A1 HK 06105438 A HK06105438 A HK 06105438A HK 1083096 A1 HK1083096 A1 HK 1083096A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- casr
- antagonist
- casr antagonist
- antagonist casr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003119131 | 2003-04-23 | ||
PCT/JP2004/005886 WO2004094362A1 (fr) | 2003-04-23 | 2004-04-23 | Antagoniste de casr |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1083096A1 true HK1083096A1 (en) | 2006-06-23 |
Family
ID=33308093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06105438.3A HK1083096A1 (en) | 2003-04-23 | 2006-05-10 | Casr antagonist casr |
Country Status (31)
Country | Link |
---|---|
US (4) | US7304174B2 (fr) |
EP (3) | EP2189439A3 (fr) |
JP (1) | JP3751312B2 (fr) |
KR (1) | KR100696927B1 (fr) |
CN (2) | CN100577633C (fr) |
AR (1) | AR044075A1 (fr) |
AT (1) | ATE452121T1 (fr) |
AU (1) | AU2004232604C1 (fr) |
BR (1) | BRPI0407097A (fr) |
CA (1) | CA2513738C (fr) |
CL (1) | CL2004000868A1 (fr) |
CO (1) | CO5640091A2 (fr) |
CY (1) | CY1109880T1 (fr) |
DE (1) | DE602004024668D1 (fr) |
DK (1) | DK1619180T3 (fr) |
ES (1) | ES2337576T3 (fr) |
HK (1) | HK1083096A1 (fr) |
HR (1) | HRP20100042T1 (fr) |
IL (1) | IL169575A (fr) |
MX (1) | MXPA05007609A (fr) |
MY (1) | MY138734A (fr) |
NO (1) | NO20054868L (fr) |
NZ (1) | NZ541188A (fr) |
PE (1) | PE20050460A1 (fr) |
PL (1) | PL1619180T3 (fr) |
PT (1) | PT1619180E (fr) |
RU (1) | RU2315036C2 (fr) |
SI (1) | SI1619180T1 (fr) |
TW (1) | TWI329628B (fr) |
WO (1) | WO2004094362A1 (fr) |
ZA (1) | ZA200505587B (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
JPWO2004106280A1 (ja) * | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | CaSRアンタゴニスト |
US20070155819A1 (en) * | 2004-02-06 | 2007-07-05 | Marquis Robert W Jr | Calcilytic compounds |
CN101437490A (zh) * | 2006-04-20 | 2009-05-20 | 安美基公司 | 稳定乳液配方 |
WO2008121386A2 (fr) | 2007-03-30 | 2008-10-09 | Amgen Inc. | Procédés de traitement de troubles intestinaux |
WO2009148052A1 (fr) * | 2008-06-05 | 2009-12-10 | 旭化成ファーマ株式会社 | Composé de sulfonamide et son application |
JP5628687B2 (ja) | 2008-12-24 | 2014-11-19 | 第一三共株式会社 | インダニル化合物 |
CA2748249C (fr) | 2008-12-24 | 2013-07-02 | Daiichi Sankyo Company, Limited | Composes amine cycliques |
WO2010103429A1 (fr) * | 2009-03-10 | 2010-09-16 | Pfizer Inc. | Dérivés de l'acide 1,1-(diméthyl-éthylamino)-2-hydroxy-propoxy]-éthyl}-3-méthyl-biphényl-4-carboxylique utiles en tant qu'antagonistes des récepteurs du calcium |
WO2010104882A1 (fr) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Procédés de modulation de la motilité des spermatozoïdes |
PE20120520A1 (es) * | 2009-03-26 | 2012-05-14 | Japan Tobacco Inc | Proceso para producir compuesto de acido carboxilico |
WO2010113860A1 (fr) * | 2009-03-31 | 2010-10-07 | 第一三共株式会社 | Composé biphényle-amine cyclique |
WO2010136035A2 (fr) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Composés inédits modulant les récepteurs du calcium et leur utilisation pharmaceutique |
WO2010136037A1 (fr) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Nouveaux composés modulant le récepteur sensible au calcium, et leur utilisation pharmaceutique |
CN103228619A (zh) | 2010-11-26 | 2013-07-31 | 利奥制药有限公司 | 钙传感受体活性化合物 |
JP2014500882A (ja) | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
RU2013128968A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительного рецептора |
US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
CN104583177B (zh) * | 2012-08-27 | 2016-09-07 | 卢平亚特兰蒂斯控股有限公司 | 作为钙敏感受体调节剂的芳基烷基胺化合物 |
MX2018015464A (es) | 2016-06-13 | 2019-05-27 | Syneurx Int Taiwan Corp | Uso de benzoato de litio para tratar trastornos del sistema nervioso central. |
TW202122410A (zh) * | 2019-12-09 | 2021-06-16 | 大陸商北京拓界生物醫藥科技有限公司 | 鈣敏感受體激動劑化合物及其應用 |
US20220040112A1 (en) | 2020-08-04 | 2022-02-10 | Calcilytix Therapeutics, Inc. | Formulations of triphenyl calcilytic compounds |
WO2022060987A1 (fr) | 2020-09-18 | 2022-03-24 | Calcilytix Therapeutics, Inc. | Composés triphényl calcilytiques destinés au traitement de l'hypocalcémie autosomique dominante de type 1 (adh1) |
WO2024220796A1 (fr) | 2023-04-21 | 2024-10-24 | Calcilytix Therapeutics, Inc. | Traitement de l'hypoparathyroïdie à l'aide de composés triphényle calcilytiques |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE633760A (fr) * | 1963-06-18 | |||
DD207203A1 (de) * | 1982-06-21 | 1984-02-22 | Peter Meisel | Verfahren zur herstellung von epoxypropylethern |
DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
US5276008A (en) * | 1990-08-09 | 1994-01-04 | Bayer Aktiengesellschaft | Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones |
EP0901459B1 (fr) | 1996-04-09 | 2005-06-29 | Nps Pharmaceuticals, Inc. | Composes calcilytiques |
US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
DE69711519T2 (de) * | 1996-09-05 | 2002-10-31 | Eli Lilly And Co., Indianapolis | Carbazolanaloge als selektive beta3-adrenergische Agonisten |
UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
US20020052509A1 (en) | 1998-04-08 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds and method of use |
MY121054A (en) | 1998-04-08 | 2005-12-30 | Smithkline Beecham Corp | Calcilytic compounds as calcium receptor antagonists. |
AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
US6334338B1 (en) | 1998-07-02 | 2002-01-01 | Lucent Technologies Inc. | Sol gel process of making a fiber preform with removal of oxide particles |
EP1112073A4 (fr) | 1998-08-12 | 2002-10-25 | Smithkline Beecham Corp | Composes calcilytiques |
EP1104411A4 (fr) | 1998-08-12 | 2002-10-24 | Smithkline Beecham Corp | Composes calcilytiques |
CA2347474C (fr) * | 1998-10-23 | 2008-08-26 | F. Hoffmann-La Roche Ag | Heterocycles d'azote bicycliques |
PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
EP1206520A1 (fr) * | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Composants de formulation a action rapide, compositions et procedes de nettoyage utilisant ces composants |
IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
MY159417A (en) | 2000-01-24 | 2017-01-13 | Smithkline Beecham Corp | Calcilytic compounds |
US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
KR20030017642A (ko) | 2000-07-21 | 2003-03-03 | 스미스클라인 비참 코포레이션 | 칼실리틱 화합물 |
DE60136187D1 (de) * | 2000-08-11 | 2008-11-27 | Japan Tobacco Inc | Calciumrezeptor-antagonisten |
IL155522A0 (en) | 2000-10-25 | 2003-11-23 | Smithkline Beecham Corp | Calcilytic compounds |
DE60124148T2 (de) | 2000-10-25 | 2007-09-06 | Smithkline Beecham Corp. | Kalzilytische verbindungen |
AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
US6864267B2 (en) | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
JPWO2004106280A1 (ja) * | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | CaSRアンタゴニスト |
-
2004
- 2004-04-23 CN CN200480002843A patent/CN100577633C/zh not_active Expired - Fee Related
- 2004-04-23 KR KR1020057013977A patent/KR100696927B1/ko not_active IP Right Cessation
- 2004-04-23 ZA ZA200505587A patent/ZA200505587B/en unknown
- 2004-04-23 PL PL04729243T patent/PL1619180T3/pl unknown
- 2004-04-23 WO PCT/JP2004/005886 patent/WO2004094362A1/fr active Application Filing
- 2004-04-23 EP EP09177717A patent/EP2189439A3/fr not_active Withdrawn
- 2004-04-23 RU RU2005123985/04A patent/RU2315036C2/ru not_active IP Right Cessation
- 2004-04-23 BR BR0407097-6A patent/BRPI0407097A/pt not_active IP Right Cessation
- 2004-04-23 MY MYPI20041512A patent/MY138734A/en unknown
- 2004-04-23 NZ NZ541188A patent/NZ541188A/en not_active IP Right Cessation
- 2004-04-23 AU AU2004232604A patent/AU2004232604C1/en not_active Ceased
- 2004-04-23 TW TW093111360A patent/TWI329628B/zh not_active IP Right Cessation
- 2004-04-23 EP EP10179435.2A patent/EP2308828A3/fr not_active Withdrawn
- 2004-04-23 US US10/830,480 patent/US7304174B2/en active Active
- 2004-04-23 JP JP2005505801A patent/JP3751312B2/ja not_active Expired - Lifetime
- 2004-04-23 ES ES04729243T patent/ES2337576T3/es not_active Expired - Lifetime
- 2004-04-23 SI SI200431348T patent/SI1619180T1/sl unknown
- 2004-04-23 EP EP04729243A patent/EP1619180B1/fr not_active Expired - Lifetime
- 2004-04-23 CL CL200400868A patent/CL2004000868A1/es unknown
- 2004-04-23 MX MXPA05007609A patent/MXPA05007609A/es active IP Right Grant
- 2004-04-23 PT PT04729243T patent/PT1619180E/pt unknown
- 2004-04-23 DE DE602004024668T patent/DE602004024668D1/de not_active Expired - Lifetime
- 2004-04-23 DK DK04729243.8T patent/DK1619180T3/da active
- 2004-04-23 AR ARP040101388A patent/AR044075A1/es unknown
- 2004-04-23 CA CA2513738A patent/CA2513738C/fr not_active Expired - Fee Related
- 2004-04-23 CN CN200910253477A patent/CN101723921A/zh active Pending
- 2004-04-23 AT AT04729243T patent/ATE452121T1/de active
- 2004-04-23 PE PE2004000403A patent/PE20050460A1/es not_active Application Discontinuation
-
2005
- 2005-07-07 IL IL169575A patent/IL169575A/en not_active IP Right Cessation
- 2005-10-19 CO CO05106148A patent/CO5640091A2/es active IP Right Grant
- 2005-10-21 NO NO20054868A patent/NO20054868L/no not_active Application Discontinuation
-
2006
- 2006-05-10 HK HK06105438.3A patent/HK1083096A1/xx not_active IP Right Cessation
-
2007
- 2007-08-17 US US11/840,739 patent/US20080255042A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/412,964 patent/US20090326058A1/en not_active Abandoned
-
2010
- 2010-01-22 HR HR20100042T patent/HRP20100042T1/hr unknown
- 2010-03-10 CY CY20101100234T patent/CY1109880T1/el unknown
-
2011
- 2011-12-23 US US13/336,205 patent/US20120301552A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1083096A1 (en) | Casr antagonist casr | |
ZA200603879B (en) | Substituted indazole-O-glucosides | |
IL175490A0 (en) | Substituted indazole-o-glucosides | |
ZA200603880B (en) | Substituted indole-O-glucosides | |
EP1680131A4 (fr) | Indole- o -glucosides substitues | |
DE502004003476D1 (en) | Standfuss | |
DE502004006683D1 (en) | Injection-locked-oscillator-schaltkreis | |
DE602004013036D1 (en) | Us | |
ZA200600430B (en) | Substituted spirobenzazepines | |
DE502004004146D1 (en) | Pyrazolverbindungen | |
DE112004002769D2 (en) | Schienengeführtes transportsystem | |
DE10394343D2 (en) | Berührungslose biometrische erkennung | |
EP1664013A4 (fr) | Composes calcilytiques | |
GB2398601B (en) | Catch | |
GB0409607D0 (en) | Antagonist | |
GB0308744D0 (en) | Counterweights | |
AU2833P (en) | Baltinrose Gaura lindheimeri | |
AU2834P (en) | Baltinblus Gaura lindheimeri | |
GB0523346D0 (en) | Structures | |
GB0301104D0 (en) | Freeze-cast structures | |
GB0310882D0 (en) | Novel structures | |
GB0307336D0 (en) | Nets | |
GB0307522D0 (en) | Nets | |
GB0304064D0 (en) | Receptors | |
GB0308309D0 (en) | Receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140423 |